NEXT SUPER STOCK Worksport (NASDAQ: WKSP) Innovation Pipeline & Explosive Revenue Growth!
NEXT SUPER STOCK: Worksport (NASDAQ: WKSP) New Product Launches and distribution channel growth CEO update!
Chief Executive Officer & President, Swk Holdings
Search every verified Jody. Staggs interview, podcast appearance, and on-the-record quote β each transcript cross-checked by AI and human review to confirm speaker identity. Jody Staggs, President and CEO of SWK Holdings, participated in a conference call on October 10, 2025, regarding Runway Growth Finance's acquisition of SWK. Staggs stated that SWK is a specialty finance company focused on the healthcare and life science industries, providing minimally diluted financing to small and midsize commercial-stage life science companies. He noted that as of August 2025, SWK had completed financings with 58 parties, deploying $867 million of capital since inception, and that the portfolio had generated mid-teens gross returns on capital. Staggs said the combined entity would have increased capacity to issue larger checks while remaining in Runway's target investment range of $20 million to $45 million. On a September 5, 2025 earnings call, Staggs discussed SWK's sale of the majority of its royalty assets and the Mod 3 subsidiary for approximately book value. He described the remaining portfolio as $234 million in performing loans yielding 14.1% with a leaner cost structure, and stated that SWK is now focused on high-yield debt. On the Q2 2025 earnings call, Staggs reported that SWK had returned $49 million to shareholders through a $4 per share special dividend and an additional $3 million through share repurchases. He attributed a measured pace of deployments to increased capital in private credit and SWK's cost of capital, and noted that NIH scientific funding cuts had impacted some portfolio companies that are vendors into that channel.
“It's a pleasure to join the Runway team on the call and speak to the portfolio we built at SWK and how we complement Runway's existing capabilities.”
“As David mentioned, SWK is a specialty finance company focused on the healthcare and life science industries. We provide minimally diluted financing to small and midsize commercial stage life science companies.”
“Our credit underwriting is anchored by identifying innovative products that have barriers to entry through FDA approval, robust intellectual property, strong clinical data and physician preference. We believe such products provide tangible collateral to secure appropriate levels of leverage.”
“Historically, our target financing size has been $5 million to $25 million and our focus has been on secured first lien loans and royalty monetizations.”
NEXT SUPER STOCK: Worksport (NASDAQ: WKSP) New Product Launches and distribution channel growth CEO update!
Runway Growth Finance Conference Call on Acquisition of SWK Holdings | Oct 10, 2025. Twitter - https://twitter.com/i101inΒ ...
SWK Holdings Q2 2025 Earnings Conference Call. Twitter - https://twitter.com/i101in #earningscall #StockMarketNews Q2 2025Β ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Jody. Staggs.